缅北强奸

At a press conference at the Marriott Chateau Champlain, the MUHC will present the details of a new treatment that promises to revolutionize the treatment of Non-Hodgkin's Lymphoma.

The new treatment, now available for the first time after clearance by Health Canada, has already been used on 15 patients at the MUHC. "After a single dose, 80 percent of patients resistant to chemotherapy and immunotherapy responded to the treatment," says Dr. Galal, Director of the Stem Cell Transplant Program of the MUHC. "Thirty percent of these were complete remissions." Additionally, the new therapy does not result in the hair loss and nausea associated with traditional treatments like chemotherapy. The revolutionary new treatment, liquid radiotherapy, is administered on an outpatient basis within one week as opposed to the usual six to eight months of traditional chemotherapy. "There is no need to admit the patient to the hospital during the treatment," explains Galal. "They can continue with their usual routines without any interference to their lifestyle."

Micheline Trahan was told there was nothing more that could be done to treat her Non-Hodgkin's Lymphoma. After contacting Dr. Galal and receiving one round of this liquid radiotherapy, she is now in complete remission. "There is no evidence of lymphoma," says Galal.

Dr. Ahmed Galal and patient Micheline Trahan will be available for interviews at the press conference on Thursday, September 8, 2005, at 11:00 am at the Mariott Chateau Champlain, Salle Neufchatel, 1 Place du Canada (514-878-9000).